MSAB | Dr.Evidence

Calum MacRae

MD, PhD, BSc

Chairman

Dr. MacRae is Vice-Chair for Scientific Innovation in the Department of Medicine at Brigham and Women’s Hospital (BWH), an Associate Professor of Medicine at Harvard Medical School, a leading investigator at the BWH Genomics Center, and an expert member of BWH’s Cardiovascular Genetics Program, which evaluates, diagnoses and manages care for inherited cardiac disorder patients. . Dr. MacRae is a cardiologist and geneticist whose clinical interests include investigating new phenotypes and how research findings can be systematically implemented into clinical care. He holds five patents, has authored over 160 peer-reviewed publications and received research funding from the National Institutes of Health’s National Human Genome Research Institute.

Dr. MacRae received his MD from the University of Edinburgh College of Medicine. He completed two internal medicine residency programs: one at Wellcome Trust Centre for Neuroimaging in London and the other at BWH. He completed a fellowship in cardiovascular disease at Massachusetts General Hospital and is board certified in internal medicine and cardiovascular disease.

Michael Klag

MD, MPH

Member

Dr. Klag is the former Dean of the Johns Hopkins Bloomberg School of Public Health and is chair of the Association of Schools of Public Health and chair of the NIH Advisory Board on Clinical Research.

He is a world-renowned kidney disease epidemiologist whose scientific contributions have been in the prevention and epidemiology of kidney disease, hypertension and cardiovascular disease. Dr. Klag directs one of the longest-running longitudinal studies in existence, the Precursors Study, which began in 1946. Previously, he was Director of the Division of General Internal Medicine and was the first Vice Dean for Clinical Investigation at the Johns Hopkins School of Medicine. Dr. Klag is the author of more than 200 publications and was the Editor-in-Chief of the Johns Hopkins Family Health Book.

Dr. Klag earned his MD at the University of Pennsylvania and his MPH from the Johns Hopkins School of Hygiene and Public Health.

David Tovey

MB.ChB., FRCGP

Member

Dr. Tovey is Co-Editor in Chief for the Journal of Clinical Epidemiology. He was Editor-in-Chief of The Cochrane Library for over 10 years, responsible for ensuring the quality and relevance of Cochrane Reviews and also for providing support for initiatives aimed at increasing their impact on clinical practice and health policy. He worked previously as Editorial Director for the BMJ Evidence Centre, which is the division of the BMJ Group that produces evidence-based resources for health professionals and the public. Dr. Tovey worked as a General Practitioner in urban practice in South London for 15 years until 2003.

Dr. Tovey is a Fellow of the UK Royal College of General Practitioners.

Frank Rockhold

PhD, ScM, BA

Member

Dr. Rockhold is a Professor of Biostatistics and Bioinformatics at Duke University Medical Center, Affiliate Professor of Biostatistics at Virginia Commonwealth University, and Managing Partner of HunterRockhold, Inc. His 40+-year career includes senior research positions at Lilly, Merck, and GlaxoSmithKline, where he retired as Chief Safety Officer and Senior Vice President of Global Clinical Safety and Pharmacovigilance. He has held faculty appointments at six universities. Dr. Rockhold served for nine years on the board of directors of the non-profit CDISC, most recently as Chairman, and is past president of the Society for Clinical Trials. He is a past member of the PCORI Clinical Trials Advisory Panel and is currently on the boards of the Frontier Science and Technology Research Foundation, Datavant, and an advisor to EMA. Dr. Rockhold has been a leader in the scientific community in promoting data disclosure and transparency in clinical research and is widely published in major scientific journals across a wide variety of research topics.

Dr. Rockhold holds a BA in Statistics from The University of Connecticut, an ScM in Biostatistics from The Johns Hopkins University, and a PhD in Biostatistics from the Medical College of Virginia at Virginia Commonwealth University. He is an Elected Fellow of both the American Statistical Association and the Society for Clinical Trials, an Accredited Professional Statistician, PStat®, and a Chartered Statistician, CStat.

Ken Kobayashi

MD, FACP

Member

Dr. Kobayashi is an accomplished oncologist, clinical pharmacologist, and senior global life sciences executive. He has a deep background as a clinician-scientist, regulator, scientific diplomat and drug developer across the US, Europe, Latin America, and Japan/Asia. As a senior executive in top-tier pharmaceutical companies including Pfizer, Daiichi Sankyo, AstraZeneca, Janssen, and Novartis, he has successfully overseen the introduction of more than 28 investigational agents and been directly involved with 60 programs, including in the areas of signal transduction inhibitors, epigenetic modifiers, and inflammation/immunotherapy. His experience also includes roles at the National Cancer Institute and the Food and Drug Administration.

Kobayashi received his MD from Northwestern University Medical School, Chicago, IL, and his AB from Washington University, St. Louis, MO.

MEDICAL STRATEGY ADVISORY BOARD